+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06772623

Evaluating Safety and Optimal Doses of Telisotuzumab Adizutecan Combined With PD-1 Inhibitors in Adults With Advanced Non-Squamous NSCLC Without Prior Treatment and Genomic Alterations

Led by AbbVie · Updated on 2026-10-27

252

Participants Needed

127

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Non small cell lung carcinoma NSCLC is the most common type of lung cancer and a leading cause of cancer deaths worldwide. This research aims to evaluate adverse events and changes in disease activity when Telisotuzumab Adizutecan ABBV-400 is combined with a PD-1 immune checkpoint inhibitor in adults with advanced or metastatic non-squamous NSCLC who have not received prior treatment for advanced disease and have no actionable genomic alterations. The study is conducted in multiple phases to assess safety, efficacy, and optimal dosing. Participants are treated in two stages. The first stage involves escalating doses of intravenous Telisotuzumab Adizutecan combined with Budigalimab to find a tolerable and effective dose. In the second stage, participants are randomized into three groups two groups receive different optimized doses of Telisotuzumab Adizutecan combined with Pembrolizumab, and one group receives standard care, which includes Pembrolizumab, Pemetrexed, and either Carboplatin or Cisplatin, followed by Pembrolizumab and Pemetrexed. The total study duration is approximately 33 months. Participants attend regular visits at approved hospitals or clinics during the study. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect tracking. Researchers measure dose-limiting toxicities, objective response, progression-free survival, duration of response, disease control, overall survival, and subgroup responses based on PD-L1 and c-Met status. Safety and efficacy outcomes are observed for up to about 33 months.

CONDITIONS

Brief Title

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here